APA

Barker A. J., Gibson K. H., Grundy W., Godfrey A. A., Barlow J. J., Healy M. P., Woodburn J. R., Ashton S. E., Curry B. J., Scarlett L., Henthorn L. & Richards L. (20010927). Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. : Bioorganic & medicinal chemistry letters.

Chicago

Barker A J, Gibson K H, Grundy W, Godfrey A A, Barlow J J, Healy M P, Woodburn J R, Ashton S E, Curry B J, Scarlett L, Henthorn L and Richards L. 20010927. Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. : Bioorganic & medicinal chemistry letters.

Harvard

Barker A. J., Gibson K. H., Grundy W., Godfrey A. A., Barlow J. J., Healy M. P., Woodburn J. R., Ashton S. E., Curry B. J., Scarlett L., Henthorn L. and Richards L. (20010927). Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. : Bioorganic & medicinal chemistry letters.

MLA

Barker A J, Gibson K H, Grundy W, Godfrey A A, Barlow J J, Healy M P, Woodburn J R, Ashton S E, Curry B J, Scarlett L, Henthorn L and Richards L. Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. : Bioorganic & medicinal chemistry letters. 20010927.